Male Urogenital Diseases Clinical Trials

7 recruiting

Male Urogenital Diseases Trials at a Glance

7 actively recruiting trials for male urogenital diseases are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Amsterdam, Utrecht, and Arnhem. Lead sponsors running male urogenital diseases studies include The Netherlands Cancer Institute, Jinling Hospital, China, and Pathos AI, Inc..

Browse male urogenital diseases trials by phase

Treatments under study

About Male Urogenital Diseases Clinical Trials

Looking for clinical trials for Male Urogenital Diseases? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Male Urogenital Diseases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Male Urogenital Diseases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 2

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Penile CancerUrogenital NeoplasmsPenile Squamous Cell Carcinoma+3 more
The Netherlands Cancer Institute27 enrolled2 locationsNCT06353906
Recruiting

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

CarcinomaCarcinoma, Renal CellNeoplasms+10 more
Jinling Hospital, China39 enrolled1 locationNCT06676527
Recruiting
Phase 2

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NeoplasmsNeoplasms by SiteUrinary Bladder Neoplasm+8 more
The Netherlands Cancer Institute90 enrolled9 locationsNCT06237920
Recruiting
Phase 1

Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures

Male Urogenital DiseasesUrologic DiseasesUrethral Stricture+1 more
Wake Forest University Health Sciences10 enrolled2 locationsNCT03258658
Recruiting
Not Applicable

The Radium-select Study

Male Urogenital DiseasesmCRPC
The Netherlands Cancer Institute60 enrolled5 locationsNCT06659926
Recruiting
Phase 4

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

NeoplasmsMetastatic Prostate CancerNeoplasms by Site+8 more
VA Greater Los Angeles Healthcare System15 enrolled1 locationNCT06706921